The clinical relevance of high tumor mutation burden or PD-L1 expression in MM on immune checkpoint blockades still remains unknown, thus further investigation would reveal their potential as a predictor of response to immune checkpoint inhibitors. This evidence concerns the gene CD274 and Miyoshi myopathy.